Christopher DelOrefice
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
ResMed Q4 2026 Earnings Call Transcript Released. ResMed has released the transcript for its Q4 2026 earnings call, providing investors with detailed insights into the company's recent performance. This follows a quarterly earnings preview and places the stock within a broader market forecast for the mHealth sector. The release offers a factual record of management's comments on financial results and strategic direction.
Transaction History
| ULTA | ▲ Buy | Grant | 4,219 | $0 | 3/31/2026 | View on chart |
| ULTA | ▲ Buy | Grant | 1,825 | $0 | 12/9/2025 | View on chart |
| ULTA | ▲ Buy | Grant | 3,649 | $0 | 12/9/2025 | View on chart |
| BDX | ▲ Buy | Grant | 6,006 | $0 | 11/26/2025 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 4,245 | $0 | 11/26/2025 | View on chart |
| RMD | ▲ Buy | Grant | 1,073 | $0 | 11/20/2025 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 278 | $0 | 9/1/2025 | View on chart |
| BDX | ▲ Buy | Grant | 4,884 | $0 | 11/26/2024 | View on chart |
| BDX | ▲ Buy | Grant | 9,015 | $0 | 11/26/2024 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 5,192 | $0 | 11/26/2024 | View on chart |
| RMD | ▲ Buy | Grant | 1,083 | $0 | 11/20/2024 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 466 | $0 | 9/7/2024 | View on chart |
| RMD | ▲ Buy | Grant | 267 | $0 | 9/3/2024 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 254 | $0 | 9/1/2024 | View on chart |
| BDX | ▲ Buy | Grant | 3,325 | $0 | 11/26/2023 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 812 | $0 | 11/26/2023 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 601 | $0 | 9/7/2023 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 353 | $0 | 9/1/2023 | View on chart |
| BDX | ▲ Buy | Grant | 3,087 | $0 | 11/26/2022 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 269 | $0 | 11/26/2022 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 506 | $0 | 9/7/2022 | View on chart |
| BDX | ▲ Buy | Grant | 2,674 | $0 | 9/1/2022 | View on chart |
| BDX | ▲ Buy | Grant | 2,608 | $0 | 11/26/2021 | View on chart |
| BDX | ▲ Buy | Grant | 4,359 | $0 | 9/7/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Ulta Beauty faces caution on softer 2026 guidance
Ulta Beauty issued softer guidance for the second half of 2026, prompting analysts to advise caution despite the current 'lipstick effect' in consumer spending. While the company is being watched as a retail pick for the upcoming holiday season, the revised outlook suggests potential headwinds ahead. The stock remains near its 52-week high, with an RSI of 74.8 indicating strong recent momentum.
Ulta Beauty faces caution on softer 2026 guidance. Ulta Beauty issued softer guidance for the second half of 2026, prompting analysts to advise caution despite the current 'lipstick effect' in consumer spending. While the company is being watched as a retail pick for the upcoming holiday season, the revised outlook suggests potential headwinds ahead. The stock remains near its 52-week high, with an RSI of 74.8 indicating strong recent momentum.